These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma. Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650 [TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Herrmann K; Erkan M; Dobritz M; Schuster T; Siveke JT; Beer AJ; Wester HJ; Schmid RM; Friess H; Schwaiger M; Kleeff J; Buck AK Eur J Nucl Med Mol Imaging; 2012 May; 39(5):846-51. PubMed ID: 22278320 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study. Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837 [TBL] [Abstract][Full Text] [Related]
7. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma. Yamane T; Takaoka A; Kita M; Imai Y; Senda M Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262 [TBL] [Abstract][Full Text] [Related]
8. 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT. Chen H; Li Y; Wu H; Sun L; Lin Q; Zhao L; An H Strahlenther Onkol; 2015 Feb; 191(2):141-52. PubMed ID: 25163419 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging. Wang FL; Tan YY; Gu XM; Li TR; Lu GM; Liu G; Huo TL Chin Med J (Engl); 2016 Dec; 129(24):2926-2935. PubMed ID: 27958224 [TBL] [Abstract][Full Text] [Related]
10. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients. Johnbeck CB; Knigge U; Langer SW; Loft A; Berthelsen AK; Federspiel B; Binderup T; Kjaer A J Nucl Med; 2016 Dec; 57(12):1851-1857. PubMed ID: 27469355 [TBL] [Abstract][Full Text] [Related]
12. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer? Schaefferkoetter JD; Carlson ER; Heidel RE J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746 [TBL] [Abstract][Full Text] [Related]
14. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes. Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857 [TBL] [Abstract][Full Text] [Related]
16. 3'-Deoxy-3'- Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456 [TBL] [Abstract][Full Text] [Related]
17. Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined Sachpekidis C; Goldschmidt H; Kopka K; Kopp-Schneider A; Dimitrakopoulou-Strauss A EJNMMI Res; 2018 Apr; 8(1):28. PubMed ID: 29633046 [TBL] [Abstract][Full Text] [Related]
18. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging. Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223 [TBL] [Abstract][Full Text] [Related]
19. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532 [TBL] [Abstract][Full Text] [Related]
20. A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. Herrmann K; Buck AK; Schuster T; Rudelius M; Wester HJ; Graf N; Scheuerer C; Peschel C; Schwaiger M; Dechow T; Keller U J Nucl Med; 2011 Dec; 52(12):1898-902. PubMed ID: 22065875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]